These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 34819055)

  • 1. Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway.
    Shen C; Zhang Z; Tian Y; Li F; Zhou L; Jiang W; Yang L; Zhang B; Wang L; Zhang Y
    BMC Med; 2021 Nov; 19(1):283. PubMed ID: 34819055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.
    Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
    Andreu-Saumell I; Rodriguez-Garcia A; Mühlgrabner V; Gimenez-Alejandre M; Marzal B; Castellsagué J; Brasó-Maristany F; Calderon H; Angelats L; Colell S; Nuding M; Soria-Castellano M; Barbao P; Prat A; Urbano-Ispizua A; Huppa JB; Guedan S
    Nat Commun; 2024 Apr; 15(1):3552. PubMed ID: 38670972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
    Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
    Zhang Q; Yang C; Ma Z; Ye L; Wu Y; Zhong C; Shi Y; Zhu M
    Mol Carcinog; 2024 Aug; 63(8):1611-1620. PubMed ID: 38780147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
    Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
    Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
    Xia W; Chen J; Hou W; Chen J; Xiong Y; Li H; Qi X; Xu H; Xie Z; Li M; Zhang X; Li J
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
    Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
    Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
    Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
    Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
    Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
    Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.